30% Flip Ideas

[Pennybuster]

$AMRN



Amarin Home Page: http://www.amarincorp.com/

Vascepa (icosapent ethyl) Home Page: http://www.vascepa.com/savings.shtml



NASDAQ quote: http://www.nasdaq.com/symbol/amrn

yahoo quote: http://finance.yahoo.com/q/h?s=AMRN

AMRN company page on SA: http://seekingalpha.com/symbol/amrn?source=search_general&s=amrn




VASCEPA prescription spreadsheet: https://docs.google.com/spreadsheet/ccc?key=0AmTJU8mIVSebdGFUY253Y3BsTDBzbWRXSFVjbDZ0bHc#gid=12
Amarin Patent Spreadsheet :https://docs.google.com/spreadsheet/ccc?key=0Av_k_WaYce2IdDRKaWR1TmctcXVnMUhJQnlwbzEzeUE#gid=0

finviz page (headlines and basic stats); http://www.finviz.com/quote.ashx?t=AMRN&ty=c&ta=0&p=d

StreetInsider AMRN data page (headlines and analysts); http://www.streetinsider.com/stock_lookup.php?LookUp=Get+Quote&q=amrn



Investor Presentation (Apr'2013): http://files.shareholder.com/downloads/AMRN/2410758917x0x651653/CC47C992-CAF5-4A08-8DC6-F1DBF0AD5DB7/Amarin_Investor_Presentation_April_2013.pdf

Investor Presentation (Apr'2012): http://www.amarincorp.com/downloads/investor-presentation.pdf

Amarin SEC filings: http://investor.amarincorp.com/sec.cfm

Vascepa FDA Orange Book page: http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=202057&Product_No=001&table1=OB_Rx
Vascepa CDER Medical / Clinical Review (July 25, 2012): http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057Orig1s000MedR.pdf ;

FDA MAPP 5021.1 : http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM340273.pdf
(MANUAL OF POLICIES AND PROCEDURES, Naming of Drug Products Containing Salt Drug Substances)


~~~~~~~~~~~~~~~~~~~~~~
General:

Good & Bad Cholesterol - http://www.americanheart.org/presenter.jhtml?identifier=180



U.S. health system/CDC - http://uk.reuters.com/article/2011/02/01/us-heart-usa-idUKTRE70N4JD20110201?feedType=RSS&feedName=healthNewsMolt





~~~~~~~~~~~~~~~~~~~~~~

General:

The rationale for using EPA http://www.drsears.com/Portals/6/Documents/Understanding%20Eicosanoids.pdf



Marine Trial hits all EndPoints - http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=533361

Marine Trial Conf Call (Nov '10): - http://www.investorcalendar.com/IC/CEPage.asp?ID=162661

Transcript MARINE trial CC: http://files.shareholder.com/downloads/AMRN/1080589559x0x430674/E6D77DA6-F44C-405F-B479-9A5C31E7A6E3/AmarinCorporation112910_Transcript.pdf

Marine Trial Presentation - http://files.shareholder.com/downloads/AMRN/1080589559x0x423194/424D45B3-62CC-4A84-81D7-F5264EF82A11/MARINE_RESULTS_Nov_29_2010.pdf

Anchor Trial completes Enrollment - http://files.shareholder.com/downloads/AMRN/1080589559x0x428546/275b9676-c0cf-4bd0-a69b-e80e26433822/AMRN_News_2010_12_16_General_Releases.pdf

Anchor Trial hits all EndPoints - http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=569648

Anchor Trial Conf Call (Apr '11): http://www.investorcalendar.com/IC/CEPage.asp?ID=164219

Additional Marine Trial Results: http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=579260



Lovaza Label, etc



Excellent Blog Article featuring Lovaza data comparison - http://www.chasingthealpha.com/2010/11/amrn-look-at-tg-and-ldl-levels.html



http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-654_Omacor.cfm



http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021853_021654s016_omacor_toc.cfm





Various Trials, Statins/Lovaza etc:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813819/pdf/mayoclinproc_85_2_004.pdf

http://www.ncbi.nlm.nih.gov/pubmed/20877395



http://www.ncbi.nlm.nih.gov/pubmed/19002433



http://www.ncbi.nlm.nih.gov/pubmed/15250255



TriCor label, FIELD trial - http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021656s019lbl.pdf

ACCORD trial - http://www.endocrinetoday.com/view.aspx?rid=61934



Jelis Trial (Japan) - http://www.ccmdweb.org/dsl/middle.aspx?Slideid=2643&Catid=1043

transcript, ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE, 10/16/2013: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM376102.pdf